AIM2 Antibody

What is AIM2 and what are its primary functions in cellular immunity?

AIM2 (Absent in Melanoma 2) is a 40-kDa cytoplasmic protein belonging to the HIN-200 family, expressed predominantly in spleen, small intestine, peripheral blood lymphocytes, and testis tissues . As a critical component of the inflammasome complex, AIM2 functions as a pattern recognition receptor that specifically detects double-stranded viral and bacterial DNA present in the cytosol . Upon DNA binding through its HIN-200 domain, AIM2 initiates Caspase-1 activation, which subsequently processes pro-inflammatory cytokines IL-1β and IL-18 . This molecular mechanism establishes AIM2 as an essential sensor for various pathogens in the innate immune system. Additionally, AIM2 plays putative roles in tumorigenic reversion and may regulate cell proliferation processes, making it relevant for both immunology and cancer research contexts .

How is AIM2 expression regulated in different cell types?

AIM2 expression demonstrates significant cell-type specificity and is subject to complex regulatory mechanisms. In human B-cells, functional AIM2 is preferentially expressed in adult CD27+ B-cells but is notably absent in cord blood mononuclear cells . Interferon-gamma (IFN-γ) serves as a potent inducer of AIM2 expression in adult B-cells, significantly increasing AIM2 mRNA levels compared to control stimulated cells . Conversely, when adult B-cells are activated via anti-IgGAM+CD40L, they express significantly reduced levels of AIM2 mRNA . This differential expression pattern suggests developmental regulation of AIM2 expression during immune cell maturation. Beyond lymphoid tissues, AIM2 is also expressed in tumors of neuroectodermal origin, breast, ovary, and colon, indicating tissue-specific regulatory mechanisms that may be altered in pathological conditions .

What are the molecular characteristics of AIM2 protein structure?

AIM2 consists of 343 amino acids with a calculated molecular weight of 39 kDa, although the observed molecular weight in experimental conditions typically ranges between 39-42 kDa . Structurally, AIM2 contains two key functional domains: a pyrin domain (PYD) at the N-terminus that mediates protein-protein interactions with the adaptor protein ASC/TMS1, and a HIN-200 domain at the C-terminus responsible for binding cytoplasmic double-stranded DNA . This bipartite domain architecture enables AIM2 to function as a molecular bridge between pathogen detection and inflammatory signaling. The PYD domain interaction with ASC's CARD domain facilitates the recruitment and activation of caspase-1, ultimately leading to the processing of pro-inflammatory cytokines . Understanding this structural organization is crucial for designing experiments targeting specific AIM2 functions or interactions.

What are the optimal conditions for detecting AIM2 using Western blotting?

Western blotting represents one of the primary methods for AIM2 detection in experimental settings. For optimal results, researchers should consider the following protocol parameters:

• Antibody Dilution: The recommended dilution range for AIM2 antibody in Western blotting applications is 1:1000-1:6000, with precise optimization needed for specific experimental systems .

• Sample Preparation: AIM2 has been successfully detected in various cell lines including Jurkat, HeLa, MCF-7, A549, and COLO 320, as well as in mouse and rat testis tissues . Effective protein extraction requires complete cell lysis with detergent-based buffers containing protease inhibitors.

• Expected Molecular Weight: Researchers should look for bands at 39-42 kDa, which corresponds to the observed molecular weight of AIM2 .

• Positive Controls: Jurkat cells or mouse macrophages treated for 12 hours with IFN-γ and LPS provide reliable positive controls due to their high AIM2 expression .

• Detection System: Enhanced chemiluminescence (ECL) systems provide sufficient sensitivity for endogenous AIM2 detection in most experimental settings .

This methodological approach has been validated in at least 26 published studies using Western blotting for AIM2 detection , indicating its reliability and reproducibility across different experimental conditions.

What methodologies are effective for studying AIM2 inflammasome activation?

Investigating AIM2 inflammasome activation requires specialized methodologies that assess both complex formation and functional outcomes. A comprehensive experimental approach should include:

• DNA-Binding Assays: Since AIM2 activation depends on cytosolic dsDNA recognition, experiments can utilize poly dA:dT as a synthetic DNA ligand to stimulate AIM2 . Binding can be assessed through co-immunoprecipitation experiments using AIM2 antibodies.

• Inflammasome Assembly Detection: Co-immunoprecipitation assays targeting the interaction between AIM2, ASC/TMS1, and caspase-1 provide direct evidence of inflammasome formation. Immunofluorescence microscopy (1:200-1:800 antibody dilution) can visualize the characteristic "speck" formation indicative of assembled inflammasomes .

• Functional Readouts: Measuring caspase-1 activity through fluorogenic substrates and quantifying mature IL-1β and IL-18 levels via ELISA or Western blotting provides functional confirmation of inflammasome activation.

• Genetic Validation: Knockdown or knockout experimental designs can verify specificity, with at least 4 publications documenting successful use of AIM2 antibodies in KD/KO validation experiments .

• Pathogen-Induced Activation: Using DNA viruses or intracellular bacteria as physiologically relevant stimuli can provide insights into pathogen-specific AIM2 activation mechanisms .

This integrated approach enables comprehensive characterization of AIM2 inflammasome dynamics under various experimental conditions.

How can immunohistochemistry be optimized for AIM2 detection in tissue samples?

Immunohistochemistry (IHC) provides critical spatial information about AIM2 expression patterns within tissues. For optimal IHC results with AIM2 antibodies, researchers should follow these methodological guidelines:

• Antibody Dilution: A dilution range of 1:20-1:200 is recommended for IHC applications, with preliminary titration experiments advised to determine optimal conditions for specific tissue types .

• Antigen Retrieval: Heat-induced epitope retrieval using TE buffer (pH 9.0) is suggested for optimal antigen unmasking, although citrate buffer (pH 6.0) may serve as an alternative .

• Positive Control Tissues: Human testis tissue serves as a reliable positive control for AIM2 immunostaining, showing characteristic cytoplasmic localization patterns .

• Detection Systems: For sensitive detection, polymer-based detection systems are preferable to traditional avidin-biotin methods, particularly for tissues with potentially low AIM2 expression.

• Counterstaining: Light hematoxylin counterstaining allows clear visualization of AIM2-positive cells while maintaining optimal contrast.

This approach has been successfully implemented in at least 10 published studies using IHC for AIM2 detection , demonstrating its reliability across different tissue types and experimental designs.

How can AIM2 antibodies be utilized to investigate inflammasome dynamics in infectious disease models?

AIM2 plays a crucial role in host defense against various pathogens through its ability to detect cytosolic DNA. Advanced research applications utilizing AIM2 antibodies in infectious disease models should incorporate the following methodological approaches:

• Time-Course Analysis: Tracking AIM2 expression and inflammasome formation at different time points after infection provides insights into the kinetics of immune activation. Western blotting (1:1000 dilution) can quantify AIM2 protein levels, while immunofluorescence (1:200-1:800 dilution) visualizes subcellular localization changes .

• Co-Localization Studies: Dual immunostaining with antibodies against AIM2 and pathogen components or subcellular markers can reveal the spatial relationship between pathogen DNA and inflammasome assembly sites.

• Ex Vivo Analysis: Isolating primary cells from infected tissues followed by immunoprecipitation with AIM2 antibodies (1:100 dilution) can identify novel interaction partners specific to particular infection models .

• Functional Correlation: Correlating AIM2 activation (detected by antibody-based methods) with downstream functional outcomes like IL-1β secretion and pyroptosis provides a comprehensive understanding of inflammasome significance during infection.

• Genetic Complementation: In AIM2-deficient models, reintroducing wild-type or mutant AIM2 variants followed by antibody detection can establish structure-function relationships in pathogen sensing.

These methodological approaches have illuminated AIM2's role as an important sensor for numerous pathogens, with specific applications documented in studies of viral and bacterial infections .

What are the methodological considerations for examining AIM2's role in cancer biology?

AIM2's expression is altered in various cancers, with the AIM2 gene showing a high frequency of mutations in microsatellite-unstable colorectal cancers . Advanced cancer research utilizing AIM2 antibodies should consider these methodological approaches:

• Tissue Microarray Analysis: Systematic IHC screening (1:20-1:200 dilution) across different tumor types and stages can establish correlation between AIM2 expression patterns and clinical parameters .

• Gene-Protein Expression Correlation: Combining RNA sequencing data with protein-level detection via Western blotting (1:1000-1:6000 dilution) can identify post-transcriptional regulatory mechanisms affecting AIM2 in tumor cells .

• Mutation-Specific Detection: Developing and validating antibodies that specifically recognize common AIM2 mutations found in colorectal cancers would enable more precise characterization of tumor-specific alterations.

• Functional Impact Assessment: In cell line models with differing AIM2 status, antibody-based detection can monitor how AIM2 expression affects tumorigenic properties, including proliferation, migration, and response to DNA-damaging therapies.

• Tumor Microenvironment Studies: Multiplex immunostaining incorporating AIM2 antibodies can reveal the relationship between AIM2-expressing tumor cells and infiltrating immune cells within the tumor microenvironment.

This multifaceted approach leverages AIM2 antibodies to explore its dual roles in inflammation and cancer biology, potentially identifying novel therapeutic vulnerabilities in tumors with altered AIM2 expression or function.

How should AIM2 antibodies be employed in studying B-cell maturation and function?

Research has revealed that AIM2 expression is developmentally regulated in B-cells, with preferential expression in adult CD27+ B-cells and absence in cord blood mononuclear cells . Advanced B-cell immunology research utilizing AIM2 antibodies should incorporate these methodological approaches:

• Developmental Profiling: Flow cytometry using AIM2 antibodies optimized for intracellular staining can track AIM2 expression across different B-cell developmental stages from bone marrow to peripheral lymphoid tissues.

• Response to Stimulation: Monitoring AIM2 expression changes following B-cell receptor engagement or cytokine stimulation (particularly IFN-γ) via Western blotting provides insights into the regulation of AIM2 during B-cell activation .

• Correlation with Functional Outcomes: Assessing the relationship between AIM2 expression levels (detected by antibodies) and B-cell functions like antibody production, class switching, and antigen presentation can reveal previously unappreciated roles of AIM2 in adaptive immunity.

• Subcellular Localization Studies: High-resolution microscopy using immunofluorescence (1:200-1:800 dilution) can determine if AIM2 localization changes during B-cell maturation or activation .

• Comparative Analysis Across Immune Cell Types: Simultaneously analyzing AIM2 expression in B-cells, T-cells, and myeloid cells from the same donors can identify cell type-specific regulation patterns.

This systematic approach leverages AIM2 antibodies to elucidate the functional significance of differential AIM2 expression during B-cell maturation and immune responses.

What strategies can address inconsistent AIM2 antibody performance across different experimental systems?

Researchers may encounter variability in AIM2 antibody performance across different experimental platforms. Methodological solutions include:

• Antibody Validation Through Multiple Approaches: Confirm antibody specificity using at least two independent detection methods (e.g., Western blotting and immunofluorescence) and include positive controls like Jurkat cells or IFN-γ-stimulated macrophages .

• Sample-Specific Optimization: Systematically titrate antibody concentrations for each experimental system, recognizing that optimal dilutions may vary significantly between applications (WB: 1:1000-1:6000; IHC: 1:20-1:200; IF/ICC: 1:200-1:800) .

• Buffer Composition Analysis: Evaluate the impact of different lysis buffers, blocking solutions, and washing conditions on detection sensitivity and specificity, particularly when working with challenging sample types.

• Epitope Accessibility Assessment: Consider potential epitope masking due to protein-protein interactions or post-translational modifications by comparing native versus denaturing conditions.

• Cross-Reactivity Profiling: When working with novel cell lines or animal models, verify antibody specificity through knockout/knockdown controls or peptide competition assays to rule out non-specific binding.

Implementing these methodological refinements can significantly improve experimental reproducibility and confidence in AIM2 detection across diverse research applications.

How can researchers distinguish between specific and non-specific signals when using AIM2 antibodies?

Discriminating between genuine AIM2 detection and non-specific signals requires rigorous methodological controls:

• Molecular Weight Verification: True AIM2 signals should appear at 39-42 kDa in Western blotting applications . Bands at substantially different molecular weights warrant careful interpretation.

• Knockout/Knockdown Validation: Including AIM2-deficient samples as negative controls provides the most stringent specificity test, with successful application documented in at least 4 publications .

• Peptide Competition Assays: Pre-incubating the AIM2 antibody with excess immunizing peptide should eliminate specific signals while non-specific binding will persist.

• Cellular Distribution Patterns: Authentic AIM2 staining should show predominantly cytoplasmic localization consistent with its known subcellular distribution .

• Interferon Stimulation Testing: Since AIM2 expression is interferon-inducible, comparing signals between untreated and IFN-γ-treated samples can confirm signal specificity, as genuine AIM2 signals should increase following stimulation .

Incorporating these methodological controls establishes confidence in experimental findings and facilitates accurate interpretation of AIM2 expression and function across different biological systems.

What methodological approaches can examine AIM2's role beyond inflammasome activation?

While AIM2's role in inflammasome activation is well-established, emerging evidence suggests additional functions that warrant investigation using these methodological approaches:

• Protein Interactome Analysis: Immunoprecipitation with AIM2 antibodies (1:100 dilution) followed by mass spectrometry can identify novel interaction partners beyond the canonical inflammasome components .

• Transcriptional Regulation Studies: Combining AIM2 antibodies with chromatin immunoprecipitation (ChIP) methodology could reveal whether AIM2 influences gene expression directly or indirectly.

• Cell Proliferation Impact Assessment: Since AIM2 may control cell proliferation , correlative studies between AIM2 expression levels (detected via antibodies) and proliferation markers can elucidate mechanisms independent of inflammasome activation.

• Subcellular Compartmentalization Analysis: High-resolution microscopy using AIM2 antibodies for immunofluorescence (1:200-1:800 dilution) can reveal dynamic changes in AIM2 localization under different cellular conditions .

• Post-Translational Modification Mapping: Developing modification-specific antibodies (phospho-AIM2, ubiquitinated-AIM2) could uncover regulatory mechanisms controlling AIM2's diverse functions.

These methodological approaches expand AIM2 research beyond its canonical role in inflammation, potentially revealing novel functions in cell proliferation, tumor suppression, and immune regulation.

How can AIM2 antibodies facilitate investigation of interferon-mediated immune regulation?

AIM2 expression is strongly induced by interferons, particularly IFN-γ , positioning it as a valuable marker for interferon-mediated immune regulation. Methodological approaches include:

• Comparative Kinetics Analysis: Using AIM2 antibodies for Western blotting (1:1000-1:6000 dilution) to track expression following stimulation with different interferon types (α, β, γ) can reveal distinct temporal regulation patterns .

• Cell Type-Specific Responses: Flow cytometry with intracellular AIM2 staining can quantify interferon responsiveness across diverse immune cell populations within heterogeneous samples.

• Signaling Pathway Interrogation: Combining pharmacological inhibitors of interferon signaling components with AIM2 antibody detection can map the precise molecular pathways regulating AIM2 induction.

• In Vivo Interferon Response Monitoring: IHC with AIM2 antibodies (1:20-1:200 dilution) in tissues from interferon-treated or infected animals can provide spatial information about interferon activity in complex anatomical contexts .

• Interferon-Resistance Mechanisms: Comparing AIM2 induction between interferon-sensitive and interferon-resistant cell populations could identify defects in interferon signaling pathways.

This methodological framework leverages AIM2's interferon-inducible nature to gain insights into both physiological and pathological interferon responses, with implications for infectious disease, autoimmunity, and cancer immunotherapy research.